Torray Investment Partners LLC Sells 3,178 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Torray Investment Partners LLC cut its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 16.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,242 shares of the biotechnology company’s stock after selling 3,178 shares during the period. Torray Investment Partners LLC’s holdings in Blueprint Medicines were worth $1,751,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Candriam S.C.A. raised its holdings in shares of Blueprint Medicines by 30.0% during the second quarter. Candriam S.C.A. now owns 52,066 shares of the biotechnology company’s stock valued at $5,611,000 after purchasing an additional 12,001 shares during the last quarter. Arizona State Retirement System raised its stake in Blueprint Medicines by 2.6% during the 2nd quarter. Arizona State Retirement System now owns 16,285 shares of the biotechnology company’s stock valued at $1,755,000 after buying an additional 414 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Blueprint Medicines by 28.5% during the 2nd quarter. Victory Capital Management Inc. now owns 264,995 shares of the biotechnology company’s stock valued at $28,561,000 after buying an additional 58,796 shares during the period. Rhumbline Advisers boosted its stake in shares of Blueprint Medicines by 6.0% in the 2nd quarter. Rhumbline Advisers now owns 91,543 shares of the biotechnology company’s stock worth $9,866,000 after buying an additional 5,160 shares during the last quarter. Finally, nVerses Capital LLC grew its holdings in shares of Blueprint Medicines by 3,100.0% in the second quarter. nVerses Capital LLC now owns 3,200 shares of the biotechnology company’s stock worth $345,000 after acquiring an additional 3,100 shares during the period.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Debra Durso-Bumpus sold 333 shares of the company’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $111.15, for a total transaction of $37,012.95. Following the sale, the insider now directly owns 43,763 shares in the company, valued at approximately $4,864,257.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Philina Lee sold 41,913 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the transaction, the insider now directly owns 34,729 shares in the company, valued at approximately $3,236,395.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Debra Durso-Bumpus sold 333 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $111.15, for a total transaction of $37,012.95. Following the completion of the sale, the insider now directly owns 43,763 shares of the company’s stock, valued at approximately $4,864,257.45. The disclosure for this sale can be found here. Insiders sold 128,947 shares of company stock worth $13,065,852 over the last 90 days. 4.21% of the stock is owned by insiders.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock traded down $4.98 during trading on Friday, reaching $86.43. 1,543,250 shares of the stock traded hands, compared to its average volume of 704,941. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of -17.97 and a beta of 0.63. Blueprint Medicines Co. has a 52-week low of $43.89 and a 52-week high of $121.90. The business has a fifty day simple moving average of $102.87 and a two-hundred day simple moving average of $99.29.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.49. The business had revenue of $138.20 million for the quarter, compared to the consensus estimate of $104.02 million. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The company’s revenue was up 139.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.19) EPS. Sell-side analysts expect that Blueprint Medicines Co. will post -3.99 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BPMC. Baird R W raised Blueprint Medicines to a “strong-buy” rating in a report on Friday, August 2nd. Barclays boosted their target price on shares of Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a research report on Monday, July 29th. Oppenheimer increased their price target on shares of Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, July 8th. Stephens started coverage on shares of Blueprint Medicines in a research note on Tuesday, May 14th. They set an “overweight” rating and a $140.00 price target on the stock. Finally, Robert W. Baird upped their price objective on Blueprint Medicines from $112.00 to $127.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $120.00.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.